Method of treating malignant mesothelioma
AssigneeThe University of Tokyo
InventorsChikao Morimoto, Kei Ohnuma, Teruo Inamoto
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic agent for malignant mesothelioma comprising a substance which inhibits binding of CD26 to extracellular matrix such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The present invention also relates to a method of treating malignant mesothelioma, which comprises administering the substance to a patient in need thereof.
Claims22
A pharmaceutical composition for treating malignant mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, comprising a substance which inhibits binding of CD26 to extracellular matrix.
A kit for treating malignant mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, comprising an anti-CD26 antibody and an effector cell specific to the antibody.
A method for inhibiting growth of a malignant mesothelioma cell, lung cancer cell, renal cancer cell, liver cancer cell, or other malignant cell expressing CD26, which comprises contacting a malignant mesothelioma cell, lung cancer cell, renal cancer cell, liver cancer cell, or other malignant cell expressing CD26 with a substance that inhibits binding of CD26 to extracellular matrix.
A method for inhibiting growth of a malignant mesothelioma cell, lung cancer cell, renal cancer cell, liver cancer cell, or other malignant cell expressing CD26, which comprises contacting the malignant mesothelioma cell, lung cancer cell, renal cancer cell, liver cancer cell, or other malignant cell expressing CD26 and an effector cell with an anti-CD26 antibody, wherein the effector cell is a cell specific to the antibody.
A method for lysing a malignant mesothelioma cell, lung cancer cell, renal cancer cell, liver cancer cell, or other malignant cell expressing CD26, which comprises contacting the malignant mesothelioma cell, lung cancer cell, renal cancer cell, liver cancer cell, or other malignant cell expressing CD26 and an effector cell with an anti-CD26 antibody, wherein lysis of the cell is caused by antibody-dependent cell-mediated cytotoxicity and wherein the effector cell is a cell specific to the antibody.
A method for detecting malignant transformation of mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, which comprises collecting a sample from a patient with mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, and measuring the expression level of CD26 in the sample.
A diagnostic agent for malignant mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, comprising an anti-CD26 antibody.
A kit for diagnosing malignant mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, comprising an anti-CD26 antibody.
A method of screening for a substance for treating malignant mesothelioma, lung cancer, renal cancer, liver cancer, or other malignancies associated with CD26 expression, which comprises contacting a CD26-positive cell with a test substance, and measuring the expression level of p27 in the cell.
(canceled)
Dependencies are inferred from the claim text.